Do analysts rate LPCN or EOCN?

Lipocine presently has a consensus price target of $4.00, suggesting a potential upside of 146.91%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor LPCN or EOCN?

In the previous week, Lipocine had 10 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 11 mentions for Lipocine and 1 mentions for Galmed Pharmaceuticals. Lipocine's average media sentiment score of 0.86 beat Galmed Pharmaceuticals' score of 0.75 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EOCN or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EOCN or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -73.68% -60.88% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer EOCN or ?

Given 's higher probable upside, analysts plainly believe is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, EOCN or ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A N/A N/A N/A N/A N/A

Is EOCN or more profitable?

's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -73.68% -60.88% N/A N/A N/A

Does the media prefer EOCN or ?

In the previous week, had 1153 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 1154 mentions for and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat 's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 251 Very Positive mention(s) 287 Positive mention(s) 315 Neutral mention(s) 197 Negative mention(s) 104 Very Negative mention(s) Neutral

Do analysts prefer EOCN or DARE?

Dare Bioscience has a consensus price target of $6.50, indicating a potential upside of 769.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer EOCN or DARE?

In the previous week, Dare Bioscience had 5 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 6 mentions for Dare Bioscience and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Dare Bioscience's score of 0.30 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACTU or EOCN?

Actuate Therapeutics currently has a consensus price target of $10.50, indicating a potential upside of 2,151.77%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ACTU or EOCN?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is ACTU or EOCN more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Galmed Pharmaceuticals N/A -73.68% -60.88%

Does the media favor ACTU or EOCN?

In the previous week, Actuate Therapeutics had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Actuate Therapeutics' score of 0.61 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Galmed Pharmaceuticals (EOCN) Competitors

$2.84 -0.32 (-10.13%)

As of 01:01 PM Eastern

Compare

EOCN vs. LPCN, ZIVO, CYCN, DARE, and ACTU

Should you buy Galmed Pharmaceuticals stock or one of its competitors? Galmed Pharmaceuticals's main competitors and comparable companies include Lipocine (LPCN), ZIVO Bioscience (ZIVO), Cyclerion Therapeutics (CYCN), Dare Bioscience (DARE), and Actuate Therapeutics (ACTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Galmed Pharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Galmed Pharmaceuticals (NASDAQ:EOCN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Lipocine has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Lipocine presently has a consensus price target of $4.00, suggesting a potential upside of 146.91%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipocine has higher revenue and earnings than Galmed Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	6.74	-$9.63M	-$1.79	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

In the previous week, Lipocine had 10 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 11 mentions for Lipocine and 1 mentions for Galmed Pharmaceuticals. Lipocine's average media sentiment score of 0.86 beat Galmed Pharmaceuticals' score of 0.75 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galmed Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

9.1% of Lipocine shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 4.7% of Lipocine shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lipocine beats Galmed Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to ZIVO Bioscience?

Galmed Pharmaceuticals (NASDAQ:EOCN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

ZIVO Bioscience has higher revenue and earnings than Galmed Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A
ZIVO Bioscience	$15.85K	1,732.17	-$7.78M	-$1.40	N/A

Galmed Pharmaceuticals has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for ZIVO Bioscience. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat ZIVO Bioscience's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
ZIVO Bioscience	Neutral

ZIVO Bioscience's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Galmed Pharmaceuticals beats ZIVO Bioscience on 6 of the 11 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to ?

Galmed Pharmaceuticals (NASDAQ:EOCN) and (:) are related companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A
	N/A	N/A	N/A	N/A	N/A

In the previous week, had 1153 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 1154 mentions for and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat 's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
	251 Very Positive mention(s)	287 Positive mention(s)	315 Neutral mention(s)	197 Negative mention(s)	104 Very Negative mention(s)	Neutral

's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%
	N/A	N/A	N/A

Given 's higher probable upside, analysts plainly believe is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Galmed Pharmaceuticals and tied by winning 4 of the 8 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Dare Bioscience?

Galmed Pharmaceuticals (NASDAQ:EOCN) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A
Dare Bioscience	$1.03M	14.28	-$13.40M	-$0.70	N/A

Galmed Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

In the previous week, Dare Bioscience had 5 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 6 mentions for Dare Bioscience and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Dare Bioscience's score of 0.30 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has a consensus price target of $6.50, indicating a potential upside of 769.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Galmed Pharmaceuticals' return on equity of -73.68% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%
Dare Bioscience	-803.80%	-748.30%	-38.75%

Summary

Dare Bioscience beats Galmed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Galmed Pharmaceuticals (NASDAQ:EOCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Actuate Therapeutics currently has a consensus price target of $10.50, indicating a potential upside of 2,151.77%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Actuate Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, Actuate Therapeutics had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Actuate Therapeutics' score of 0.61 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

Galmed Pharmaceuticals' return on equity of -73.68% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Summary

Actuate Therapeutics beats Galmed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EOCN vs. The Competition

Export

Metric	Galmed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.95M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.19	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.12	9.21	10.55	5.95
Net Income	-$10.31M	$2.84B	$3.50B	$380.75M
7 Day Performance	-38.13%	-4.00%	-3.92%	-3.96%
1 Month Performance	-38.13%	-8.07%	-8.30%	-6.81%
1 Year Performance	-75.35%	-5.86%	2.35%	-4.58%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EOCN Galmed Pharmaceuticals	0.9648 of 5 stars	$2.84 -10.1%	N/A	-73.1%	$2.95M	N/A	N/A	20	Gap Down
LPCN Lipocine	4.3213 of 5 stars	$2.25 +6.9%	$4.00 +78.2%	-47.9%	$18.43M	$1.57M	N/A	14	Gap Up High Trading Volume
ZIVO ZIVO Bioscience	N/A	$4.10 +2.2%	N/A	-50.7%	$17.28M	$15.85K	N/A	10	Gap Down
CYCN Cyclerion Therapeutics	N/A	$3.49 +3.9%	N/A	N/A	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
DARE Dare Bioscience	2.583 of 5 stars	$0.80 -3.9%	$6.50 +711.5%	-64.7%	$15.76M	$1.03M	N/A	24	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EOCN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (EOCN) Competitors

EOCN vs. LPCN, ZIVO, CYCN, DARE, and ACTU

How does Galmed Pharmaceuticals compare to Lipocine?

Summary

How does Galmed Pharmaceuticals compare to ZIVO Bioscience?

Summary

How does Galmed Pharmaceuticals compare to ?

Summary

How does Galmed Pharmaceuticals compare to Dare Bioscience?

Summary

How does Galmed Pharmaceuticals compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOCN vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (EOCN) Competitors

EOCN vs. LPCN, ZIVO, CYCN, DARE, and ACTU

How does Galmed Pharmaceuticals compare to Lipocine?

Which has more volatility & risk, LPCN or EOCN?

Do analysts rate LPCN or EOCN?

Which has higher valuation & earnings, LPCN or EOCN?

Does the media favor LPCN or EOCN?

Is LPCN or EOCN more profitable?

Do institutionals and insiders hold more shares of LPCN or EOCN?

Summary

How does Galmed Pharmaceuticals compare to ZIVO Bioscience?

Which has higher valuation & earnings, EOCN or ZIVO?

Which has more risk & volatility, EOCN or ZIVO?

Do insiders and institutionals believe in EOCN or ZIVO?

Does the media prefer EOCN or ZIVO?

Is EOCN or ZIVO more profitable?

Do analysts prefer EOCN or ZIVO?

Summary

How does Galmed Pharmaceuticals compare to ?

Do institutionals & insiders have more ownership in EOCN or ?

Which has better valuation and earnings, EOCN or ?

Does the media prefer EOCN or ?

Is EOCN or more profitable?

Do analysts prefer EOCN or ?

Summary

How does Galmed Pharmaceuticals compare to Dare Bioscience?

Which has stronger valuation and earnings, EOCN or DARE?

Which has more volatility & risk, EOCN or DARE?

Does the media prefer EOCN or DARE?

Do analysts prefer EOCN or DARE?

Do institutionals & insiders believe in EOCN or DARE?

Is EOCN or DARE more profitable?

Summary

How does Galmed Pharmaceuticals compare to Actuate Therapeutics?

Do insiders & institutionals have more ownership in ACTU or EOCN?

Do analysts prefer ACTU or EOCN?

Which has more risk and volatility, ACTU or EOCN?

Does the media favor ACTU or EOCN?

Which has higher valuation & earnings, ACTU or EOCN?

Is ACTU or EOCN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOCN vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools